AbbVie news: Buyer accumulation continues — RSI overbought, short-term hesitation after Gilgamesh acquisition

Traders Union
All News
Financial News
AbbVie Slips 0.06% Today to $222.45

Highlights

AbbVie Inc. (ABBV) trades at $222.45, maintaining a strong technical position above its MA-20 ($214.19), MA-50 ($203.42), and MA-200 ($192.02) averages.
AbbVie declared a $1.64 per share quarterly cash dividend for November 2025 and completed a $1.2 billion acquisition of Gilgamesh Pharmaceuticals' depression therapy.
Bullish momentum prevails with ABBV expected to trade between $222.60 and $224.09, but RSI at 71.23 suggests overbought conditions and possible short-term hesitation.

Shareholder returns highlighted by dividend and strategic acquisition

AbbVie's announcement of a $1.64 per share quarterly cash dividend payable in November 2025 underlines its focus on shareholder returns and supports the stock's appeal to income-focused investors. The company also completed a $1.2 billion acquisition of Gilgamesh Pharmaceuticals' lead depression therapy, adding to its therapeutic pipeline. Recent quarterly results showed robust revenue growth of 6.6% year-over-year, complemented by sustained free cash flow and institutional investor activity.

Mixed momentum signals as price tests overbought territory and resistance

Technically, bullish momentum prevails across all time frames, with AbbVie trading solidly above its short, medium, and long-term moving averages. Dynamic support is seen at $214.73 (Ichimoku Kijun), while immediate resistance sits near the recent high at $224. Momentum signals are mixed: the daily MACD remains positive, but ADX points to waning trend strength. The RSI is overbought at 71.23, in line with CCI readings, and the Stoch RSI is volatile on intraday frames. BBP shows ongoing buyer activity, yet the Awesome Oscillator signals a strong sell, highlighting underlying divergence and possible short-term hesitation.

Bullish breakout favored as rangebound trade persists near highs

In the short term, ABBV is expected to remain rangebound, trading between $222.6 and $224.09, with an average near $223.35. The probability of further upside is high (over 80%), supported by bullish readings from weekly moving averages, RSI, and MACD. A bullish breakout above $224 could lead to new highs, while a break below $214 would signal a period of deeper consolidation.

Viktoras Karapetjanc, analyst at Traders Union, believes AbbVie’s robust fundamentals and clear commitment to shareholder returns underpin the stock’s sustained strength above major moving averages. He notes that the successful acquisition and strong revenue growth illustrate AbbVie's strategic focus, while technicals remain mostly supportive despite some short-term overbought signals. Overall, Karapetjanc sees continued bullish momentum, with only limited downside risk as long as $214 holds. "With macro and fundamental drivers intact, I expect ABBV to challenge new highs if it breaks above $224," says Karapetjanc.

Previously it was noted that AbbVie was expected to consolidate between resistance and support levels, with over an 80% chance of further upside in the near term. The analysis highlighted ongoing bullish momentum and a rangebound trading just below recent highs as the most likely scenario.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.